Bivatuzumab mertansine

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBivatuzumab mertansine
Drug Alias NameMonoclonal antibody CD44v6-DM1 immunoconjugateAnti-CD44v6-DM1 immunoconjugateBIWI-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCD44 antigen inhibitorsApoptosis stimulantsMitosis inhibitors
TargetsCD44 antigen
Therapy Area/IndicationsHead and Neck NeoplasmsBreast NeoplasmsCarcinoma, Squamous Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunogen IncC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsBreast NeoplasmsCarcinoma, Squamous Cell

Other Information

ATC CodeN/A
Related LinksWikipedia